AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Vaxcyte Stock Plunges 37.43% on Disappointing Phase 2 Results
Generated by AI AgentAinvest Movers Radar
Monday, Mar 31, 2025 7:56 am ET1min read
On March 31, 2025, Vaxcyte's stock price plummeted by 37.43% in pre-market trading, marking a significant decline for the biotechnology company.
Vaxcyte's recent Phase 2 study results have been a major factor in the stock's decline. The company announced topline results from its Phase 2 dose-finding study of VAX-24, which did not meet expectations, leading to a sharp drop in investor confidence.
In response to the disappointing study results,
has scheduled a webcast and conference call to present the findings in detail. This move is aimed at providing transparency and addressing investor concerns, although it remains to be seen whether it will be enough to stabilize the stock price.
Ainvest Movers Radar
Knowing stock market today at a glance
Latest Articles
ASE Industrial ADR (ASX) Soars 18.64% on Robust Earnings, AI/Automotive Semiconductor Demand
Jan.06 2026
APi Group Shares Rally 7.63% on Stock Dividend Strong Q3 Results CertaSite Acquisition
Jan.06 2026
Art Technology Acquisition Corp. Shares Dive 0.20% to Record Low on SPAC, Sector Risks
Jan.06 2026
Novartis Stock Surges 3.39% on Strategic U.S. Deal, Q3 Revenue Rises 8.5%
Jan.06 2026
UDR Stock Surges 2.96% to 15-Month High on Goitia Board Appointment
Jan.06 2026
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet